Cure My Disease

Don't miss your cure!

 Log in / Sign up

New radiation approach aims to safely treat High-Risk prostate cancer

NCT ID NCT02353819

Ongoing Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 1 trial is testing a precise, high-dose radiation technique called SABR for men with high-risk prostate cancer. The goal is to find the highest safe dose to the prostate and pelvic lymph nodes while monitoring side effects. Sixty participants will receive five radiation sessions, with doses gradually increased in later groups. The study also tracks tumor response and quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic Ablative Radiotherapy (SABR)
What this could lead to
If successful, this could establish a safer, more effective radiation dose for high-risk prostate cancer, potentially improving tumor control and quality of life.
What could go wrong
This is an early phase 1 trial with only 60 participants, so results may not apply to all patients. High-dose radiation can cause side effects like urinary or bowel issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75239, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.